ArticleJournal of ovarian research2025
Research on the process and molecular mechanism of inhibiting serous ovarian cancer by PRTN3 and its inhibitor Sivelestat.
Article in Journal of ovarian research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- PRTN3 drives immunosuppression in KRAS-mutant lung adenocarcinoma through proteolytic inactivation of CXCL9.Journal for immunotherapy of cancer · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundSerous ovarian cancer (SOC) is one of the most important diseases affecting women's health in the world. It is highly occult and often detected in late stage due to the lack of specific molecular markers.
methodsWhole exon sequencing was performed on 38 serous ovarian cancer samples, and the mutated gene PRTN3 was selected by bioinformatics analysis. In vitro experiments with serous ovarian cancer cell lines SKOV3 and OVCAR8 and normal ovarian epithelial cell line IOSE80 were performed to verify the expression of PRTN3 and the effect of its inhibitor sivelestat. Xenotransplantation models in vivo also confirmed the effect of sivelestat.
resultWe found that Missense Mutation accounted for the vast majority of somatic mutations, and 263 candidate mutant genes were obtained from the mutation frequency, among which three hub gene clusters centered on SF3A2, MUC3A, and PRTN3 were identified, and PRTN3 had the strongest effect on the overall survival of the patients. Subsequently, we verified the expression of PRTN3 in serous ovarian cancer samples and cell lines, PRTN3 was highly expressed in serous ovarian cancer samples and cell lines, and sivelestat could inhibit the migration ability of serous ovarian cancer cell lines. SKOV3 cells were used to construct xenografted tumor models to explore the prospect of PRTN3 as a molecular therapeutic target for ovarian cancer and the application potential of sivelestat, which can inhibit the progression of xenografted tumors in vivo with certain safety.
conclusionsWhole exome sequencing and bioinformatics analysis identified PRTN3 as a potential molecular marker of serous ovarian cancer, and PRTN3 could significantly affect the prognosis of SOC patients. As an inhibitor of PRTN3, sivelestat can inhibit the expression of PRTN3 in SOC cell lines and reduce their migration ability in vitro. In vivo experiments showed that sivelestat can inhibit the growth of subcutaneous transplanted tumor in nude mice with certain safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.